author={A. Cruz-Jentoft and A. Sayer},
  journal={The Lancet},
Sarcopenia is a progressive and generalised skeletal muscle disorder involving the accelerated loss of muscle mass and function that is associated with increased adverse outcomes including falls, functional decline, frailty, and mortality. It occurs commonly as an age-related process in older people, influenced not only by contemporaneous risk factors, but also by genetic and lifestyle factors operating across the life course. It can also occur in mid-life in association with a range of… Expand
The ageing syndromes of sarcopenia and frailty
The diagnosis in clinical practice of sarcopenia and frailty helps to identify a group of patients at risk of adverse outcomes who could benefit from interventions including resistance exercise training and comprehensive geriatric assessment. Expand
Sarcopenia: assessment of disease burden and strategies to improve outcomes
Because sarcopenia is associated with important adverse health outcomes, such as frailty, hospitalization, and mortality, several therapeutic strategies have been identified that involve exercise training, nutritional supplementation, hormonal therapies, and novel strategies and are still under investigation. Expand
Sarcopenia: A Contemporary Health Problem among Older Adult Populations
The prevalence of sarcopenia in older adults, its etiology, prevention, and treatment techniques are reported, and physical activity and nutrition are the main studied ways to prevent sarc Openia. Expand
A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease.
Resistance training and nutritional supplementation are the primary methods for treating sarcopenia and trials with various agents, including selective androgen receptor modulators and myostatin inhibitors show promise as future treatment options. Expand
Different components of frailty in the aging subjects—The role of sarcopenia
This chapter analyzed the biological mechanisms involved in sarcopenia onset and progression, starting from changes in muscle structure and function and continuing with the role of mitochondrial dysfunction, anabolic resistance, hormonal changes, and inflammation. Expand
Development of Pharmacotherapies for the Treatment of Sarcopenia
A review of the leading programs and approaches, available findings from recent studies, and several related issues needed to facilitate the development of a safe and efficacious pharmacotherapeutic that could be used as part of a treatment plan for older men and women with sarcopenia are discussed. Expand
Exercise and Protein Intake: A Synergistic Approach against Sarcopenia
The randomized clinical trial conducted within SPRINTT will provide robust evidence on the effectiveness of exercise and nutrition at preventing negative outcomes associated with sarcopenia and physical frailty. Expand
Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Given that sarcopenia and IMRDs have strong links, further research is needed to improve patient care, and there is growing evidence linking nutrition to the prevention and treatment of sarc Openia. Expand
Molecular routes to sarcopenia and biomarker development: per aspera ad astra.
The main pathogenetic pathways of sarcopenia are discussed, with a focus on mediators that are currently in the spotlight as biomarkers and potential treatment targets. Expand
Sarcopenia measurement in research and clinical practice.
Diagnostic and case finding/screening tools for age-related (primary) sarcopenia used in research and clinical practice are outlined and their ability to reliably predict adverse clinical outcomes and patient responses to potential therapies are examined. Expand